KYNTRA BIO, INC. Retained Earnings
KYNTRA BIO, INC. (KYNB) had Retained Earnings of -$1.71 billion as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.71B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.72B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.71B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.69B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$1.71B 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$1.72B 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$1.71B 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$1.69B 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$1.89B 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$1.88B 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$1.89B 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$1.91B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$1.89B 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$1.87B 10-Q · filed 2024-05-06 | |
| 2023-12-31 | -$1.84B 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$1.79B 10-Q · filed 2023-11-06 | |
| 2023-06-30 | -$1.72B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$1.63B 10-Q · filed 2023-05-08 | |
| 2022-12-31 | -$1.56B 10-K · filed 2024-02-26 | |
| 2022-09-30 | -$1.49B 10-Q · filed 2022-11-07 | |
| 2022-06-30 | -$1.40B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$1.33B 10-Q · filed 2022-05-09 | |
| 2021-12-31 | -$1.26B 10-K · filed 2023-02-27 | |
| 2021-09-30 | -$1.13B 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$1.18B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$1.05B 10-Q · filed 2021-05-10 | |
| 2020-12-31 | -$974.01M 10-K/A · filed 2022-03-04 | |
| 2020-09-30 | -$915.38M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$948.38M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$863.07M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$784.72M 10-K · filed 2021-03-01 | |
| 2019-09-30 | -$686.60M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$637.16M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$753.16M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$715.83M 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$736.78M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$694.22M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | -$670.80M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | -$630.66M 10-K · filed 2020-03-02 | -$595.95M 10-K · filed 2018-02-27 |
| 2017-09-30 | -$573.82M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$536.09M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | -$502.90M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$509.78M 10-K · filed 2019-02-27 | -$469.74M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$435.74M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | -$411.59M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | -$435.90M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | -$451.71M 10-K · filed 2019-02-27 | -$408.06M 10-K · filed 2016-02-29 |
| 2015-09-30 | -$356.69M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | -$311.60M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$368.65M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | -$322.28M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |